Rexahn Pharmaceuticals Inc.

Rexahn Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. The company's cancer drugs have been shown to directly target cancer cells while bypassing healthy cells, demonstrating increased efficacy and reduced toxicity. These drug candidates are effective against multiple drug-resistant cancers and show they can work together with FDA-approved cancer treatments to increase efficacy. Rexahn is also developing specific biomarkers that identify which patients will be most responsive to its treatments. The company's nanotechnology-based drug delivery system has shown it can make FDA approved chemo drugs more effective.

Expert Comments:

Jerry Isaacson, LifeSci Capital (5/23/16)
"Between Rexahn's 3 clinical programs, the company is targeting 5 disease indications with a large total market opportunity (we estimate that the addressable population exceeds 100,000 patients per year in the US). . .we also estimate that lead candidate Archexin could generate between $175 to $524 million in peak annual revenues in renal cell carcinoma. There are very few treatment options for the remaining indications, which include pancreatic cancer, bladder cancer, triple-negative breast cancer, and relapsed advanced ovarian cancer, suggesting that doctors and patients will be highly motivated to use newly approved therapies."

Vernon Bernardino, FBR & Co. (5/10/16)
"Having successfully identified the maximum tolerated dose (MTD) for both Supinoxin and RX-3117, Rexahn Pharmaceuticals Inc. is now moving full speed ahead with both programs. . .we think RX-3117's speed to proof-of-concept stage reflects its clinical potential. . .based on the encouraging preclinical data that are reported so far, we think Supinoxin could become validated as a treatment for solid tumors."

"I have Rexahn Pharmaceuticals Inc. rated Buy. It has three interesting drugs right now. Supinoxin (RX-5902), a phosphorylated p68 inhibitor, is in Phase 1 for solid tumors. There's RX-3117 (fluorocyclopentenylcytosine), which I might call a 'better' gemcitabine, also in Phase 1 for, potentially, a broad spectrum of oncology indications. There is also Archexin (RX-0201), an Akt1 antisense oligonucleotide inhibitor, which is in Phase 1b/2a for metastatic renal cell carcinoma. Over the last six months or so, the company has started to generate some clinical data, and this is bolstered by what I consider to be solid preclinical data sets with regard to the efficacy of the molecules in very difficult cell line and animals models. We're looking to get interim data, maybe in H2/16, from both Supinoxin and RX-3117. These are randomized, well-designed studies, but very early stage. The interim data will be key drivers, I think. The investment community wants to see more clinical responses from these drugs, even though we already have positive anecdotal data from the earlier Phase 1 safety studies. . .right now, I would say RX-3117 and Supinoxin are the value drivers because of the investment the company is making with regard to the four well-designed clinical studies. Archexin is, in essence, on autopilot. You have some initial data, and it has had some earlier Phase 2 data as well, for renal cell cancer. We're going to get the Phase 2 data readouts for Archexin in 2017. From just a driver standpoint, the interim data from the Phase 1a/1b studies of Supinoxin and RX-3117 will really increase the visibility for Rexahn this year." read more >

Yash Batia, Seeking Alpha (3/1/16)
"Earlier this month, Rexahn Pharmaceuticals Inc. hit a milestone with identifying maximal tolerated dose and concluding the first stage of a Phase 2a trial of Archexin in combination with the chemotherapy drug everolimus in patients with metastatic renal cell carcinoma. With that, the second stage of the trial kicked off to evaluate the safety and efficacy of the combination therapy."

Joseph Pantginis, ROTH Capital Partners (2/26/16)
"Rexahn Pharmaceuticals Inc. announced an additional financing of $5M today as the company continues to expand its lead programs into proof-of-concept studies. . .it will now have a busy 2016 with the planned initiation of several Phase 1b/2a signal-seeking studies in defined tumor types. Rexahn has stated that it is in discussions with multiple companies in order to find the optimal collaborative relationship with regard to Supinoxin and RX-3117."

Sharon di Stefano, Seeking Alpha (2/23/16)
"Rexahn Pharmaceuticals Inc. makes great strides in whittling down its future disease indications using oral cancer medications. The three indications, genitourinary cancers, renal cell carcinoma and triple-negative breast cancer, show promise when exposed to Supinoxin and the company is smart to focus on these huge markets."

More Expert Comments

Experts Following This Company

Vernon Bernardino, Analyst – FBR & Co.
Andrew Fein, Managing Director and Senior Biotechnology Analyst – H.C. Wainwright & Co.
Jerry Isaacson, Managing Director and Senior Analyst – LifeSci Advisors, LifeSci Capital
Yale Jen, Analyst – Laidlaw & Company
Alan Leong, CEO – BioWatch News
Jason Napodano, Managing Director and Senior Biotech Analyst – BioNap Inc.
Joseph Pantginis, Senior Analyst – ROTH Capital Partners

The information provided above is from analysts, newsletters, the company and other contributors.

Rexahn Pharmaceuticals Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Rexahn Pharmaceuticals Inc. Content